問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

李日翔Lee, Jih-Hsiang
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

275Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李日翔

List

422Cases

2017-08-24 - 2020-12-31

Phase III

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)

  • Condition/Disease

    Small Cell Lung Cancer (SCLC)

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
4Sites

Terminated4Sites

2012-09-01 - 2016-09-01

Phase II

A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer

  • Condition/Disease

    Brain Metastases from Non-Small Cell Lung Cancer

  • Test Drug

    ABT-888 (Veliparib)

Participate Sites
6Sites

Terminated6Sites

2012-07-01 - 2015-07-31

Phase I

A Multicenter, Phase 1/1b Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Antibody, in Subjects with Advanced Solid Tumor

  • Condition/Disease

    Advance solid tumor/non-small cell lung cancer/astric/gastroesophageal junction adenocarcinoma

  • Test Drug

    ABT-700

Participate Sites
3Sites

Terminated3Sites

夏德椿
China Medical University Hospital

Division of Thoracic Medicine

2020-08-01 - 2025-07-01

Phase I

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Tumors

  • Test Drug

    ABBV-CLS-579

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-07-07 - 2026-07-31

Phase I

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma

  • Test Drug

    ABBV-514ABBV-181 (Budigalimab)

Participate Sites
5Sites

Recruiting5Sites

2019-06-01 - 2022-12-31

Phase II

A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

  • Condition/Disease

    Cutaneous Angiosarcoma

  • Test Drug

    Oraxol

Participate Sites
2Sites

Recruiting2Sites

2013-08-22 - 2015-06-30

Phase III

A randomized, double-blind, double-dummy, parallel group, international multicenter study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer.

  • Condition/Disease

    nausea and vomiting

  • Test Drug

    netupitant-palonosetron Fixed Dose Combination (FDC)

Participate Sites
7Sites

Terminated7Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2023-10-01 - 2026-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2016-09-19 - 2018-04-30

Phase I

A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects with Advanced Solid Tumor

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    OPB-111077 100-mg Tablets

Participate Sites
5Sites

Terminated4Sites

2018-04-15 - 2020-12-31

Phase I/II

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors

  • Condition/Disease

    Solid tumor

  • Test Drug

    MCLA-128

Participate Sites
1Sites

Recruiting1Sites

1 29 30 31 32 33 43
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB